SG11201502666XA - High dose extended-release potassium citrate wax matrix tablet - Google Patents

High dose extended-release potassium citrate wax matrix tablet

Info

Publication number
SG11201502666XA
SG11201502666XA SG11201502666XA SG11201502666XA SG11201502666XA SG 11201502666X A SG11201502666X A SG 11201502666XA SG 11201502666X A SG11201502666X A SG 11201502666XA SG 11201502666X A SG11201502666X A SG 11201502666XA SG 11201502666X A SG11201502666X A SG 11201502666XA
Authority
SG
Singapore
Prior art keywords
high dose
potassium citrate
matrix tablet
wax matrix
dose extended
Prior art date
Application number
SG11201502666XA
Other languages
English (en)
Inventor
Wendell G Mendoza
Rita Josefina M Santos
Kennie U Dee
Original Assignee
Wendell G Mendoza
Rita Josefina M Santos
Kennie U Dee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51428563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502666X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wendell G Mendoza, Rita Josefina M Santos, Kennie U Dee filed Critical Wendell G Mendoza
Publication of SG11201502666XA publication Critical patent/SG11201502666XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG11201502666XA 2013-02-28 2013-02-28 High dose extended-release potassium citrate wax matrix tablet SG11201502666XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PH2013/000007 WO2014133401A1 (en) 2013-02-28 2013-02-28 High dose extended-release potassium citrate wax matrix tablet

Publications (1)

Publication Number Publication Date
SG11201502666XA true SG11201502666XA (en) 2015-05-28

Family

ID=51428563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502666XA SG11201502666XA (en) 2013-02-28 2013-02-28 High dose extended-release potassium citrate wax matrix tablet

Country Status (10)

Country Link
US (1) US9295659B2 (zh)
EP (1) EP2961389B1 (zh)
JP (1) JP6164507B2 (zh)
KR (1) KR102077524B1 (zh)
CN (1) CN104994842B (zh)
ES (1) ES2640022T3 (zh)
HK (1) HK1210723A1 (zh)
PH (1) PH12015500469A1 (zh)
SG (1) SG11201502666XA (zh)
WO (1) WO2014133401A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080451A1 (ja) * 2018-10-17 2020-04-23 京都府公立大学法人 糖尿病腎症における腎線維化抑制剤
KR102274835B1 (ko) * 2019-06-17 2021-07-08 주식회사 한국팜비오 포타슘 시트레이트 조성물을 포함하는 서방형 정제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
DE102009004829A1 (de) * 2009-01-13 2010-07-22 Gkn Sinter Metals Holding Gmbh Mischung zur Verhinderung von Oberflächenflecken
JP5551895B2 (ja) * 2009-06-23 2014-07-16 旭化成せんい株式会社 布バネ材用織物
CN101791299A (zh) * 2010-01-18 2010-08-04 南京泽恒医药技术开发有限公司 一种枸橼酸钾缓释片的制备方法
CN102240272B (zh) * 2010-05-13 2013-07-10 丽珠医药集团股份有限公司 一种枸橼酸钾缓释片及其制备方法
CN102488670B (zh) * 2011-12-22 2013-05-01 苏州东瑞制药有限公司 双重缓释枸橼酸钾缓释制剂的制备方法
JP6150148B2 (ja) 2012-09-27 2017-06-21 ユナイテッド・ラボラトリーズ・インコーポレイテッド 徐放性クエン酸カリウムワックスマトリックスタブレットの製造方法

Also Published As

Publication number Publication date
EP2961389B1 (en) 2017-08-23
KR102077524B1 (ko) 2020-02-14
US20150272913A1 (en) 2015-10-01
JP6164507B2 (ja) 2017-07-19
EP2961389A4 (en) 2016-07-06
WO2014133401A1 (en) 2014-09-04
CN104994842A (zh) 2015-10-21
KR20150122620A (ko) 2015-11-02
EP2961389A1 (en) 2016-01-06
JP2016510024A (ja) 2016-04-04
PH12015500469B1 (en) 2015-04-20
PH12015500469A1 (en) 2015-04-20
ES2640022T3 (es) 2017-10-31
HK1210723A1 (zh) 2016-05-06
US9295659B2 (en) 2016-03-29
CN104994842B (zh) 2018-04-27

Similar Documents

Publication Publication Date Title
ZA201508571B (en) Modular tablet case
GB201306312D0 (en) Tablet case
GB201302901D0 (en) Ubuntu tablet
HK1215191A1 (zh) 低劑量醫藥組合物
GB201310263D0 (en) Burial capsule
ZA201508411B (en) Swallowable n-acetylcysteine tablets
SI2988585T1 (sl) Lemež z dvema diskoma
EP2857006A4 (en) DRY-COATED TABLET
HK1210722A1 (zh) 生產緩釋檸檬酸鉀蠟基質片劑的方法
IL241350A0 (en) Subprevir tablets
HK1205463A1 (zh) 含有 -羥基- -咪唑- -甲酰胺的片劑
HK1220113A1 (zh) 藥物軟明膠膠囊劑型
HK1210723A1 (zh) 高劑量檸檬酸鉀蠟基質緩釋片劑
RS60054B1 (sr) Tableta koja sadrži krospovidon
EP3069714A4 (en) Tablet
HU4589U (en) Capsule
GB201308228D0 (en) Optometrists mobile/tablet application